Investment Information

With transparent disclosure of information and communication with markets,
we will grow along with shareholders.

News Room

News Room Search
News Room List
NO Title Date Viewers
77 HanAll Biopharma and Daewoong Pharmaceutical Enter into Co-Development Agreement with NurrOn Pharmaceuticals to Develop Therapy for Parkinson’s Disease 2023-05-26 262
76 HanAll Biopharma Announces Results from Phase III randomized, double-masked active treatment-controlled VELOS-3 Trial Evaluating Tanfanercept 0.25% for Treatment of Dry Eye Disease 2023-05-19 519
75 HanAll Biopharma Reports First Quarter 2023 Results and Provides Business Update 2023-04-28 495
74 HanAll Biopharma Assigns Su-jin Park as Co-CEO to Drive Next Phase of Growth 2023-03-29 565
73 HanAll Biopharma Opens Applications for the 2023 Pharmaceutical Industry Fellowship Program 2023-03-15 625
72 HanAll Biopharma’s Licensed Partner in China Announces Positive Topline Phase 3 Results for Batoclimab in Myasthenia Gravis 2023-03-06 828
71 HanAll Biopharma Invests in Interon to Seek Collaboration Opportunities 2023-02-10 819
70 HanAll Biopharma Reports Full-Year 2022 Results and Provides Business Update 2023-02-01 1026
69 HanAll Biopharma Reports Third Quarter 2022 Results and Provides Business Update 2022-11-16 1766
68 HanAll’s Licensed Partner in China Enters Sublicense Agreement with CSPC to Further Accelerate Development of Batoclimab 2022-10-11 1878
현재 페이지1 2 3 4 5 6 7 8